Quest Diagnostics Incorporated, a leading provider of diagnostic information services, announced strong financial results for the third quarter ended September, 2025, and raised its full-year 2025 guidance following continued robust performance.

Third quarter revenues were $2.82 billion, an increase of 13.1 per cent compared to the same period in 2024.

Year-to-date, the company generated $1.4 billion in cash from operations, representing a 63.1 per cent increase from 2024.
Quest now expects full-year 2025 reported diluted EPS to range between $8.58 and $8.66, and adjusted diluted EPS between $9.76 and $9.84.

“Our third quarter performance underscores the strong demand for Quest’s comprehensive clinical solutions and the effectiveness of our growth strategy,” said Jim Davis, Chairman, CEO, and President of Quest Diagnostics. “With double-digit revenue growth, expanding partnerships, and strong execution across all segments, we continue to strengthen our position as the trusted lab engine for healthcare and wellness organizations nationwide. Given our solid year-to-date results, we are once again raising our full-year 2025 guidance.”

During the quarter, Quest advanced several strategic initiatives to expand its reach and enhance its capabilities. The company entered into an agreement with Corewell Health to form a major lab services joint venture in Michigan, deploying its full suite of Co-Lab Solutions, including reference testing, lab analytics, supply chain, and blood management services across 21 Corewell hospitals. Annual revenues for Co-Lab Solutions are expected to approach $1 billion next year as the partnership scales.

Quest also completed the acquisition of select dialysis testing assets from Fresenius Medical Care and began scaling laboratory testing for Fresenius’ U.S. dialysis centers, serving approximately 200,000 patients annually.

Further expanding its presence in consumer health and digital wellness, Quest announced collaborations with WHOOP, a leading human performance company, and ŌURA Health, maker of the world’s most advanced smart ring, to integrate Quest’s lab testing capabilities into their mobile platforms.

In technology and innovation, Quest partnered with Epic on Project Nova, a multi-year initiative designed to streamline systems and enhance patient and provider experiences across electronic health record platforms. The company also published new data in Neurology Clinical Practice validating the accuracy of its AD-Detect tests for aiding Alzheimer’s disease diagnosis.

Quest continues to strengthen its oncology capabilities with the FDA Breakthrough Device Designation for its Haystack MRD test, developed to guide postoperative cancer therapy decisions. The company is collaborating with Mass General Brigham and the Rutgers Cancer Institute to evaluate the test in clinical studies.

In recognition of its ongoing commitment to innovation and employee well-being, Quest was named a Top Corporate Wellness Innovator by Fast Company. Additionally, the company appointed Thomas Koch, an experienced leader in the laboratory and medical device industries, as Senior Vice President of Research & Development.

“Quest Diagnostics remains focused on advancing diagnostic innovation, improving health outcomes, and expanding access to high-quality testing through our national scale and trusted partnerships,” Davis added. “Our performance this quarter reflects the continued success of that mission.”